Telephone
61.3.9670.3273
Address
Level 4 100 Albert Road South Melbourne, Victoria (VIC) 3205
Description
Patrys Ltd. engages in the commercialization of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. Its pipeline includes PAT-DX1 antibody fragment, PAT-DX3 full sized antibody, and PAT-DX1-NP conjugated to nanoparticles. The company was founded by Daniel Devine on December 8, 2006 and is headquartered in South Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.01 - 0.03
Trade Value (12mth)
AU$11,809.00
1 week
33.33%
1 month
-11.11%
YTD
-70.37%
1 year
-65.22%
All time high
0.619421
EPS 3 yr Growth
36.000%
EBITDA Margin
N/A
Operating Cashflow
-$6m
Free Cash Flow Return
-57.00%
ROIC
-69.70%
Interest Coverage
N/A
Quick Ratio
10.40
Shares on Issue (Fully Dilluted)
2056m
HALO Sector
Healthcare
Next Company Report Date
22-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 October 12 |
CEO Presentation to AGM 2012
×
CEO Presentation to AGM 2012 |
31 March 23 |
Updated guidance for PAT-DX1 phase 1 clinical study
×
Updated guidance for PAT-DX1 phase 1 clinical study |
31 July 08 |
CEO presentation- 6th Annual Australian Biotechnology Summit
×
CEO presentation- 6th Annual Australian Biotechnology Summit |
31 January 23 |
Appendix 4C - Quarterly - 31 December 2022
×
Appendix 4C - Quarterly - 31 December 2022 |
31 January 22 |
Appendix 4C - Quarterly - 31 December 2021
×
Appendix 4C - Quarterly - 31 December 2021 |
31 August 22 |
Appointment of Non-Executive Director
×
Appointment of Non-Executive Director |
31 August 22 |
Initial Director's Interest Notice
×
Initial Director's Interest Notice |
30 September 08 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 November 11 |
CEO`s Presentation to AGM 2011
×
CEO`s Presentation to AGM 2011 |
30 January 23 |
Patrys Receives R&D Tax Incentive Refund
×
Patrys Receives R&D Tax Incentive Refund |
30 August 22 |
PAT-DX1 From Engineering Run Meets all Specification Tests
×
PAT-DX1 From Engineering Run Meets all Specification Tests |
30 August 22 |
Appendix 4E and 2022 Annual Report
×
Appendix 4E and 2022 Annual Report |
30 August 22 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
30 August 16 |
Appendix 4E and 2016 Annual Report
×
Appendix 4E and 2016 Annual Report |
30 August 10 |
Appendix 4E and 2010 Annual Report
×
Appendix 4E and 2010 Annual Report |
30 August 10 |
Patrys 2010 Annual Report
×
Patrys 2010 Annual Report |
29 November 23 |
Notification of cessation of securities - PAB
×
Notification of cessation of securities - PAB |
29 November 23 |
Change of Director's Interest Notices x2
×
Change of Director's Interest Notices x2 |
29 August 17 |
Appendix 4E and 2017 Annual Report
×
Appendix 4E and 2017 Annual Report |
28 September 21 |
Company Overview Presentation - September 2021
×
Company Overview Presentation - September 2021 |
28 September 12 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
28 September 10 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
28 September 07 |
Annual Report to shareholders
×
Annual Report to shareholders |
28 October 22 |
Appendix 4C - Quarterly - 30 September 2022
×
Appendix 4C - Quarterly - 30 September 2022 |
28 October 11 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
28 July 22 |
Appendix 4C - Quarterly - 30 June 2022
×
Appendix 4C - Quarterly - 30 June 2022 |
28 February 22 |
Stable Cell Line for Production of PAT-DX3 Established
×
Stable Cell Line for Production of PAT-DX3 Established |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.